Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
The phase III, multicenter, randomized, placebo-controlled PreCISe trial assessed glatiramer acetate (GA) effects in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS). To assess the neuroprotective effect of GA in a subset of patients in the PreCISe trial, we us...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer Berlin Heidelberg
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705142/ |